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Summary 
A sub-set of 38 individuals with type 1 diabetes that fulfilled a strict criterion of “normal” 
classification for all 7 measures of neuropathy at baseline, were identified and followed. 
Corneal nerve morphology, as captured with corneal confocal microscopy demonstrated the 
greatest, and most sustained degeneration over a 4 year period.   
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Progression of neuropathy is difficult to monitor, and this has been suggested to contribute to 
an inability to prove efficacy of novel treatments
1
.  One strategy to demonstrate monotonic 
worsening is selection of cohorts without neuropathy at enrolment
1
. Past studies, including 
analyses on the same cohort described here, have defined an absence of neuropathy at 
enrolment using a composite score of signs and symptoms.  This may incorrectly include 
false negatives, where individuals fail neuropathy measures, but are classified “non-
neuropathic” by a composite score.  By only including individuals with all normal tests of 
neuropathy at baseline, we hypothesized that a truly non-neuropathic cohort would be 
identified, providing a better baseline to demonstrate neuropathy development and 
progression.  
The LANDMark study
2
 is a 5-year observational study investigating corneal markers of 
diabetic neuropathy. We report here findings from the Australian site, based at Queensland 
University of Technology. Of 159 individuals with type 1 diabetes, 141 completed 4 years of 
follow up.  Of these, 38 were classified as “normal” at baseline, according to seven different 
measures of neuropathy; cold, warm and vibration perception (according to instrument-
specified age-dependent normal ranges), testing with monofilament (no failures), neuropathy 
disability score
3
 (NDS)(≤2), electrophysiology (reduced peroneal nerve conduction velocity 
(PNCV) compared with age-matched controls in our laboratory; ≥45meters/second if <54 
years old, and ≥ 39 meters/second if ≥ 54 years old) and corneal confocal microscopy (CCM) 
(corneal nerve fibre length (CNFL) >14.1mm/mm
2
)
4
. These 38 individuals had annual visits 
for 4 years, and at each visit, were classified as “normal” or “abnormal” for each measure.  
Visits also included assessment of risk factors.   
McNemar’s test was used to determine any differences in the proportions of individuals that 
failed the seven measures. T-tests were used to test for differences in characteristics between 
those with and without a CNFL deficit at year 4. 
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The study was approved by the Queensland University of Technology, Princess Alexandra 
Hospital and Mater Health Services Human Research Ethics Committees. 
Of the 141 individuals who completed baseline to year 4 visits, individuals without 
neuropathy at baseline (n=38) were younger (38±12 vs 52±15 years, P<0.001), had a shorter 
duration of diabetes (12±9 vs 24±15 years, P<0.001),  better glycemic control (HbA1c) 
(7.6±1.0 vs 8.2±1.4 %, P=0.02), lower triglycerides (0.80±0.33 vs 1.11±0.65 mmol/L, 
P=0.007), lower systolic blood pressure (119±13 vs 129±18 mmHg, P=0.001), and lower 
BMI (24.9±3.1 vs 27.5±5.1, P=0.004) than those who tested abnormal for any neuropathy 
measure at baseline (n=103).   There was no difference in gender, total, high-density 
lipoprotein, or low-density lipoprotein cholesterol, or diastolic blood pressure (all P>0.05) 
between the two groups. 
Figure 1 shows the number of individuals failing each measure of neuropathy at each visit in 
the cohort of 38 without neuropathy at baseline.  Only those individuals who also failed the 
same measure again at year 4 are included.  Of all seven measures of neuropathy, more 
people developed a deficit in CNFL than any other by year 4 (n=7).  Of the 38 individuals 
without neuropathy at baseline, there were no differences in age, gender, duration of diabetes, 
glycemic control, lipids, blood pressure or BMI (all P>0.05) between those who did and did 
not develop a reduction in CNFL.  
McNemar’s test determined that a greater proportion of individuals developed deficits in 
CNFL and PNCV than in WST (p=0.016 and p=0.031 respectively), Monofilament (p=0.016 
and p=0.031 respectively) or NDS (p=0.016 and p=0.031 respectively).  
This is the first study to use such strict criteria for defining patients with “no neuropathy” at 
baseline, and demonstrated that CNFL showed the earliest and most sustained deterioration 
over 4 years.  This supports previous work showing that CCM is better able to demonstrate 
early degeneration
4-6
 and regeneration
7
 of small nerve fibres.  
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It is difficult to evaluate the performance of any neuropathy measure when no single measure 
stands out as an ideal gold standard.  Comparison of tests to one another or to a composite 
criteria is the usual approach.  Interpretation of such results is difficult when it is unclear if 
lack of association between novel and established measures indicates poor specificity or 
evidence of a new, distinct measure of neural deficit.  By using the approach of the current 
study, we are not comparing one test to another, but observing which measures show 
sustained deterioration.   
This method may not be practical for most studies and trials of neuropathy, due to the strict 
criteria of normality leading to a significant reduction in participant numbers.  It likely falsely 
excludes individuals without neuropathy who had a false positive for even a single measure at 
baseline.  However, it provides greater confidence of identifying a truly “non-neuropathic” 
cohort at baseline, which may better demonstrate the earliest neural deterioration.   
Assuming diabetic neuropathy is monotonic in nature, where individuals failed some tests at 
a single time point, but tested “normal” at all other time points might be considered “false 
positives”.  Compared to the other measures, and given it identified a high number of 
individuals with sustained deterioration, CNFL had few such false positives over the 4-years 
(n=5), indicating that the high numbers identified by CNFL was not due to poor sensitivity.   
Peroneal amplitude and latency, and sural sensory nerve latency, amplitude and conduction 
velocity were also analysed. Individuals developed abnormal values at year 4 as assessed 
with sural amplitude (n=6) and latency (n=10), however, these parameters were not included 
due to the difficulty or inability to measure the sural nerve in many individuals. Furthermore, 
regardless of which measure was included, CNFL consistently performed slightly better than 
the nerve conduction parameter.   
One argument may be that the CNFL deficit is due to aging.  We have shown that CNFL 
reduces by 0.05mm/mm
2
 per year in healthy controls
8
, and as such, would expect a reduction 
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of 0.2mm/mm
2 
over 4 years.  These 7 individuals demonstrated a greater reduction in CNFL 
over the 4 years than expected due to aging (averages ± standard deviation, mm/mm
2
); 17.5 ± 
2.3 (baseline), 17.4 ± 2.9 (year 1), 16.7 ± 2.7 (year 2), 15.6 ± 2.8 (year 3), 12.4 ± 1.2 (year 4).  
 
The small numbers included in this study make it difficult to draw definitive conclusions, 
nevertheless this study provides a novel method to analyse cohorts in longitudinal studies of 
diabetic neuropathy. Furthermore, it makes a strong argument that CNFL demonstrates the 
earliest and most consistent changes in neuropathy status.  
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Figure 1. The number of individuals failing each measure of neuropathy at each visit in a 
cohort that were classified as “normal” for all measures of neuropathy at baseline (n=38).  
Only those individuals that also failed the same measure at year 4 are included. Some 
individuals failed some of these tests at a single time-point, but tested “normal” at all other 
time points.  This included 5 for CNFL, 13 for PNCV, 3 for cold sensation, 1 for vibration 
sensation and 3 for NDS.   (note: no individuals failed WST, monofilament and NDS in any 
year.) 
 
 
CCM: corneal confocal microscopy, PNCV: peroneal nerve conduction velocity, CST: cold 
sensation threshold, WST: warm sensation threshold, VPT: vibration perception threshold, 
NDS: neuropathy disability score. 
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